{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:20:07Z","timestamp":1790086807761,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Fund of China","doi-asserted-by":"crossref","award":["82422024"],"award-info":[{"award-number":["82422024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Fund for Outstanding Young Scholars","award":["JQ22020"],"award-info":[{"award-number":["JQ22020"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Fund of China","doi-asserted-by":"crossref","award":["82422024"],"award-info":[{"award-number":["82422024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Fund for Outstanding Young Scholars","award":["JQ22020"],"award-info":[{"award-number":["JQ22020"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The degree of culprit artery stenosis affects the risk of early neurological deterioration (END) after acute ischemic stroke (AIS). The TREND trial demonstrated the efficacy of tirofiban in preventing END in patients with AIS. We aimed to investigate whether the degree of intracranial artery stenosis affects the efficacy of tirofiban in preventing END in patients with AIS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We conducted a post hoc analysis of the TREND trial, which enrolled patients within 24\u2009h of onset and randomly allocated to receive intravenous tirofiban or oral aspirin. We stratified the stenosis degrees into three subgroups: no stenosis, mild-to-moderate stenosis (stenosis &amp;lt;70%), and severe stenosis or occlusion (stenosis \u2a7e70%). The primary endpoint is END4 defined as an increase of the NIHSS \u2a7e4 within 72\u2009h after randomization. Secondary outcomes include END2 (defined as an increase of NIHSS \u2a7e2) within 72\u2009h after randomization, the proportion of mRS 0\u20131 and 0\u20132 at 90\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 296 patients were analyzed. In patients with severe stenosis or occlusion, tirofiban significantly reduced the incidence of END4 (5.7% vs 30.8%, adjusted OR 0.156, 95% CI 0.028\u20130.873, adjusted p\u2009=\u20090.034), whereas its effects in preventing END4 were similar to those of aspirin in patients with no stenosis (2.4% vs 4.6%, adjusted OR 0.193, 95% CI 0.018\u20132.083, adjusted p\u2009=\u20090.175) or mild-to-moderate stenosis (2.9% vs 10.0%, adjusted OR 0.171, 95% CI 0.015\u20131.943, adjusted p\u2009=\u20090.155). The p value for interaction between stenosis subgroups and treatment was 0.513. Furthermore, tirofiban significantly reduced the incidence of END2 in patients with mild-to-moderate stenosis (5.9% vs 22.5%, OR 0.146, 95% CI 0.022\u20130.951, adjusted p\u2009=\u20090.044) and severe stenosis or occlusion (11.4% vs 43.6%, adjusted OR 0.140, 95% CI 0.036\u20130.540, adjusted p\u2009=\u20090.004). A significant improvement in favorable outcomes with a 90-day mRS of 0\u20131 was observed only in patients with mild-to-moderate stenosis (85.3% vs 70.0%, adjusted OR 4.617, 95% CI 1.077\u201319.798, adjusted p\u2009=\u20090.039).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusion<\/jats:title>\n                    <jats:p>Tirofiban may significantly reduce the incidence of END in patients with severe arterial stenosis or occlusion. Further studies are required to confirm the effects of intracranial artery stenosis on the benefits of intravenous tirofiban.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov; identifier: NCT04491695.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873251319151","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T09:00:49Z","timestamp":1739523649000},"page":"919-928","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of tirofiban in preventing neurological deterioration in acute ischemic stroke with intracranial artery stenosis: A post hoc analysis of the TREND Trial"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4105-0816","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing, China 2"},{"name":"Beijing Key Laboratory of Hypoxic Conditioning Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-2744","authenticated-orcid":false,"given":"Xunming","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China 1"},{"name":"Beijing Key Laboratory of Hypoxic Conditioning Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China 3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2026012115061984400_bibr1-23969873251319151","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/jnnp-2014-308327","article-title":"Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications","volume":"86","author":"Seners","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012115061984400_bibr2-23969873251319151","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00415-017-8490-3","article-title":"Revisiting 'progressive stroke': incidence, predictors, pathophysiology, and management of unexplained early neurological deterioration following acute ischemic stroke","volume":"265","author":"Seners","year":"2018","journal-title":"J Neurol"},{"key":"2026012115061984400_bibr3-23969873251319151","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/0366-6999.222343","article-title":"Early neurological deterioration after recanalization treatment in patients with acute ischemic stroke: a retrospective tudy","volume":"131","author":"Zhang","year":"2018","journal-title":"Chin Med J"},{"key":"2026012115061984400_bibr4-23969873251319151","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000113732","article-title":"Steno-occlusive arterial disease and early neurological deterioration in acute ischemic stroke","volume":"25","author":"Ois","year":"2008","journal-title":"Cerebrovasc Dis"},{"key":"2026012115061984400_bibr5-23969873251319151","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.21037\/apm-20-1175","article-title":"FLAIR vascular hyperintensity: an unfavorable marker of early neurological deterioration and short-term prognosis in acute ischemic stroke patients","volume":"9","author":"Zhu","year":"2020","journal-title":"Ann Palliat Med"},{"key":"2026012115061984400_bibr6-23969873251319151","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/bc.bc_68_22","article-title":"Where are we heading in post-China angioplasty and stenting for symptomatic intracranial severe stenosis era?","volume":"9","author":"Xue","year":"2023","journal-title":"Brain Circ"},{"key":"2026012115061984400_bibr7-23969873251319151","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1161\/STROKEAHA.116.015414","article-title":"Is unexplained early neurological deterioration after intravenous thrombolysis associated with thrombus extension?","volume":"48","author":"Seners","year":"2017","journal-title":"Stroke"},{"key":"2026012115061984400_bibr8-23969873251319151","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.nic.2007.03.001","article-title":"Mechanisms of ischemic stroke secondary to large artery atherosclerotic disease","volume":"17","author":"Derdeyn","year":"2007","journal-title":"Neuroimaging Clin N Am"},{"key":"2026012115061984400_bibr9-23969873251319151","doi-asserted-by":"crossref","DOI":"10.1161\/STROKEAHA.108.532465","article-title":"Hemodynamic factors and perfusion abnormalities in early neurological deterioration","volume":"40","author":"Alawneh","year":"2009","journal-title":"Stroke"},{"key":"2026012115061984400_bibr10-23969873251319151","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamaneurol.2024.0146","article-title":"Clopidogrel plus aspirin vs aspirin alone in patients with acute mild to moderate stroke: the ATAMIS randomized clinical trial","volume":"81","author":"Chen","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026012115061984400_bibr11-23969873251319151","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012115061984400_bibr12-23969873251319151","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012115061984400_bibr13-23969873251319151","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(13)70079-6","article-title":"Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials","volume":"12","author":"Whiteley","year":"2013","journal-title":"Lancet Neurol"},{"key":"2026012115061984400_bibr14-23969873251319151","first-page":"515","article-title":"Platelet glycoprotein IIb\/IIIa receptor inhibitor tirofiban in acute ischemic stroke","volume":"79","author":"Yang","year":"2019","journal-title":"Drugs"},{"key":"2026012115061984400_bibr15-23969873251319151","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamaneurol.2024.0868","article-title":"Effects of tirofiban on neurological deterioration in patients with acute ischemic stroke: a randomized clinical trial","volume":"81","author":"Zhao","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026012115061984400_bibr16-23969873251319151","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/bc.bc_93_23","article-title":"Safety and efficacy of tirofiban in preventing neurological deterioration in acute ischemic stroke (TREND): protocol for an investigator-initiated, multicenter, prospective, randomized, open-label, masked endpoint trial","volume":"10","author":"Wang","year":"2024","journal-title":"Brain Circ"},{"key":"2026012115061984400_bibr17-23969873251319151","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"2026012115061984400_bibr18-23969873251319151","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.45.8.1488","article-title":"The warfarin-aspirin symptomatic intracranial disease study","volume":"45","author":"Chimowitz","year":"1995","journal-title":"Neurology"},{"key":"2026012115061984400_bibr19-23969873251319151","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"2026012115061984400_bibr20-23969873251319151","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/bc.bc_56_23","article-title":"Endogenous defense mechanism-based neuroprotection in large-vessel acute ischemic stroke: a hope for future","volume":"10","author":"Goel","year":"2024","journal-title":"Brain Circ"},{"key":"2026012115061984400_bibr21-23969873251319151","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ Res"},{"key":"2026012115061984400_bibr22-23969873251319151","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5853\/jos.2022.02754","article-title":"Wall shear stress associated with stroke occurrence and mechanisms in middle cerebral artery atherosclerosis","volume":"25","author":"Woo","year":"2023","journal-title":"Stroke"},{"key":"2026012115061984400_bibr23-23969873251319151","doi-asserted-by":"crossref","first-page":"111107","DOI":"10.1016\/j.ejrad.2023.111107","article-title":"Association of culprit plaque enhancement ratio, hypoperfusion and HbA1c with recurrent ischemic stroke in patients with atherosclerotic stenosis of the middle cerebral artery","volume":"168","author":"Yu","year":"2023","journal-title":"Eur J Radiol"},{"key":"2026012115061984400_bibr24-23969873251319151","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/svn-2018-000228","article-title":"Perfusion and plaque evaluation to predict recurrent stroke in symptomatic middle cerebral artery stenosis","volume":"4","author":"Lyu","year":"2019","journal-title":"Stroke Vasc Neurol"},{"key":"2026012115061984400_bibr25-23969873251319151","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/bc.bc_54_23","article-title":"Enhancing the clinical value of single-phase computed tomography angiography in the assessment of collateral circulation in acute ischemic stroke: a narrative review","volume":"10","author":"Yang","year":"2024","journal-title":"Brain Circ"},{"key":"2026012115061984400_bibr26-23969873251319151","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/bc.bc_83_23","article-title":"Compromised dynamic cerebral autoregulation is a hemodynamic marker for predicting poor prognosis even with good recanalization after endovascular thrombectomy","volume":"10","author":"Ran","year":"2024","journal-title":"Brain Circ"},{"key":"2026012115061984400_bibr27-23969873251319151","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/bc.bc_89_22","article-title":"Direct transfer for thrombectomy in patients with large vessel occlusions on computed tomography angiography results in safe revascularization","volume":"9","author":"Eaton","year":"2023","journal-title":"Brain Circ"},{"key":"2026012115061984400_bibr28-23969873251319151","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/bc.bc_15_24","article-title":"Intravenous thrombolysis plus tirofiban versus tirofiban alone in Caucasian patients with acute anterior choroidal or paramedian pontine infarction","volume":"10","author":"Toudou-Daouda","year":"2024","journal-title":"Brain Circ"},{"key":"2026012115061984400_bibr29-23969873251319151","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13686","article-title":"Subtyping treatment response of tirofiban in acute ischemic stroke based on neuroimaging features","volume":"17","author":"Han","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026012115061984400_bibr30-23969873251319151","doi-asserted-by":"crossref","first-page":"785836","DOI":"10.3389\/fneur.2021.785836","article-title":"Efficacy and safety of tirofiban in clinical patients with acute ischemic stroke","volume":"12","author":"Han","year":"2021","journal-title":"Front Neurol"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873251319151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873251319151","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/3\/919\/65867007\/23969873251319151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/3\/919\/65867007\/23969873251319151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:07:42Z","timestamp":1769026062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/10\/3\/919\/8376514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873251319151","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,1]]},"published":{"date-parts":[[2025,9,1]]}}}